AI Tools Streamlining Clinical Workflow Improving Patient-Physician Relationship with Kyna Fong Elation Health

Jeff Glazier, CEO of General Oncology, is taking a unique approach to treating cancer by using older chemotherapy drugs with broad action but in novel combinations designed to avoid the incidental toxicity.  Their primary drug in trials is GO-4 which is focused on shutting down DNA repair in cancer cells to overcome drug resistance.  While testing in patients with stage 4 pancreatic cancer, this approach was designed to combat tumor heterogeneity by targeting fundamental processes like proliferation that are common to all cancer cells within a tumor. Jeff explains, "We're actually taking a different approach than a lot of companies are. And I would say there are really two approaches because we have two different things on, we have a clinical trial right now where we're using old chemotherapy drugs in a new way, and when you combine them together, you really get just a different result. We're trying to shut down DNA repair and kill cancer cells. But the other really interesting thing, and I think it’s underlying general vision, is chemotherapy drugs long ago had very broad action, and with broad action comes unwanted incidental toxicity. And over the years, it's been huge in the industry, or moving towards specific drugs that target specific things and have less incidental toxicity. The unfortunate side effect is that cancer cells can evolve around a drug if there's too much specificity. So we're taking a pretty novel approach with our business of going after drugs that have broad action, but we found a way, we believe, to do it in a way that doesn't have incidental toxicity." "I certainly feel that you want to have more than one attack. If you only do one, the cancer cells can evolve around it. The drug resistance approach I was referring to was what we call GO-4 in our clinical trial, and we're altering part of the cancer cells’ fundamental biology that is involved in DNA repair and shutting it down. But we're doing it in more than one way."   #GeneralOncology #PancreaticCancer #CancerAwareness #MetastaticCancer #GO4Therapy #CancerResearch #InnovativeTherapies #DrugDevelopment generaloncology.com Download the transcript here

Dr. Arup Roy-Burman, Founder and Chief Strategy and Medical Officer of Elemeno Health, is addressing the gap between established medical policies and actual frontline practice. The Elemeno microlearning platform provides just-in-time multimedia content, building confidence in high-risk, low-frequency procedures, helping support knowledge retention, and combating clinician burnout. This modern approach to learning caters to clinicians with shorter attention spans and the expectation of receiving information on the device of their choice when they need it. Arup explains, "My background is as an ICU physician, and I have practiced as an ICU director for 20-plus years. And the challenge that we had in our ICUs is how to keep our teams on the same page with constantly changing information? And on top of that, in the context of constantly changing staff, medicine is full of so many different practices, workflows, and procedures, and we expect our staff to know all of them and to be able to execute on each one of them at the time that they need to. But that's really unrealistic. There's no way that people can stay on top of it. All medical knowledge doubles every 73 days."   "When we think about today's generational workforce, as we think about just those of us who have kids, we see that attention spans, as you said, are short. People don't want to sit through a whole classroom. They can't remember that. And the way that people want to learn now and the way that they do learn, it's like one of our clients put it, it's like the "TikTokification of education." How do we deliver information on a mobile device? How do we deliver it in short, bite-sized chunks? Multimedia that you can actually consume in context when you need it." #ElemenoHealth #DigitalHealth #HealthcareInnovation #Microlearning #NurseTraining  elemenohealth.com Download the transcript here

Kourosh Davarpanah, Co-Founder and CEO of Inato, is using an AI-enabled platform to transform participation in clinical trials. The existing clinical trial system is not seen as representative of the general population, and FDA directives have addressed this lack of diversity. The Inato platform features a marketplace approach that connects trial sponsors with a broader range of hospital sites, as well as an AI tool to assist doctors in identifying patients who are eligible for trials.   Kourosh explains, "Our focus at Inato is to expand the number of patients who are able to participate in clinical research. If you think about how things have been done for the past decades, most of the patients who have the opportunity to participate are coming from the larger academic hospitals. And what this means is that typically, 5% of the sites, meaning 5% of the hospitals running research, run about 70% of all the trials globally. So this has an impact not only on the number of patients that can actually participate in trials, but it also has an impact on the type of patients. So, typically, those are going to be white patients, richer patients. And so it has a big impact also on equity and on the diversity--and ethnic diversity especially--of patients participating."   "We have two pieces of the platform. The first piece is that we're helping connect the hospitals running the trials with trials that are being run by the sponsors. So the way this works is similar to marketplaces like Airbnb, where you have the sponsor that can share any number of upcoming trials. We enable the sites to discover all the trials on the platform and showcase, based on their profiles, how many trials they have done in the past, what is the makeup of the team and doctors, etc. We're able to allow them to get selected in trials that they otherwise wouldn't be able to get selected for. So this is the first piece of it, really connecting the sites and the trials. And increasingly with AI, we've started supporting sites in actually identifying patients at scale. And this has really been a massive tech shift, where the latest generations of LLMs are able to accurately identify patients eligible for any trial with over 95% accuracy." #Inato #ClinicalTrials #ClinicalRearch #AI #MedAI #DrugDevelopment  Inato.com Download the transcript here

Javier Cuello, Founder and CEO of H+Trace highlights the significant and often overlooked problem of errors in the handling of medical samples. Issues like mislabeling, contamination, and improper shipping conditions are responsible for a majority of lab result errors, potentially leading to patient misdiagnoses. The H+Trace solution uses wireless sensors and AI to track samples, generate high-value data, and predict where errors are likely to occur. Working in Latin America and Central America has provided the company with experience in utilizing drones for shipping medical samples and organs to remote and hard-to-reach areas, while maintaining sample integrity.  Javier explains, "It all started for me when a very close friend of mine was misdiagnosed with diabetes while she was pregnant. And when I started digging into this problem, what we found out is that most lab tests today are highly reliable. Once the sample reaches the analyzer, the real danger lies in the logistics of collecting, labeling, and transporting samples prior to that. While not every mistake hurts, the patient studies showed that about 2% to 5% of errors are clinically significant, and this means over 9,000 patients every day in the US risk misdiagnosis, late treatment, and unnecessary procedures or even life-threatening consequences, all because of failures in the pre-analytic logistics."   "It's a quite new problem because over the past decades, laboratories have invested heavily in laboratory equipment and training, but the logistics of sample handling have seen little innovation. That is why roughly two-thirds of errors still occur in the pre-analytical phase." "But the reality is that most laboratories don't even know under what conditions the transport takes place. Even some of the most important labs simply receive the sample processing and send the results. So we're working with a laboratory that addresses this kind of problem, which started with labor. They have their own logistics. We started in Latin America and Central America, and now we're about to launch in the US because this is a very big problem in the US." #HTrace #Logistics #LabSamples #Sensors #ShippingLabSamples h-trace.com Download the transcript here

Kyna Fong, Co-Founder and CEO of Elation Health, is developing AI tools that prioritize patient care and automate documentation and referrals to help alleviate physician burnout and improve the patient-provider relationship. Kyna emphasizes the critical role of interoperability in effective primary care, enabling primary care physicians to coordinate care. She also noted the recent White House initiative on interoperability, which encouraged the private sector to cooperate in data-sharing initiatives, now that AI can be used to overcome technical issues of data integration and analysis.  Kyna explains, "Clinical-first is not new for Elation. It's actually our founding product philosophy. When we first started building Elation, what we observed was that so many tools that were built for physicians to use and their electronic health records were very much oriented around billing needs and, in a lot of ways, followed a billing-first philosophy. And so we created Elation to really focus on clinical first, which means putting patient care first and foremost."   "The way that we are approaching AI is as a tool. It's a tool in our toolkit. It's a how and when we think about all the pressures and burdens on physicians, especially primary care physicians, that prevent them from being able to focus on their patients. We take each of those and think about, well, how can AI make this easier? And so there are a variety of areas where we've deployed AI to help our customers. There are the clear, fairly pervasive ones today that start with something like an ambient scribe that helps with documentation, saving multiple hours per day. It's radically transformative."  #ElationHealth #AI #MedAI #PrimaryCare #Physicians #EHR #HealthIT #DigitalHealth elationhealth.com Download the transcript here  

Hamid Ghanadan, CEO of LINUS, discusses the findings of the company's recent state-of-the-science research, a semiannual survey that tracks sentiment and confidence within the life sciences. Notably, a growing gap in optimism exists between academic and biopharma scientists.  As a result, academics are seeking partnerships at a new level due to economic pressures from grant cancellations, the need for multidisciplinary collaboration to solve complex problems, and the desire for a stronger collective voice. AI was identified as the top priority for academia and biopharma, as is the need to improve communication with the public about scientific discoveries and medical advancements. Hamid explains, "We started the state-of-the-science research four years ago, so this is the eighth time that we've done it. And what we're really doing is measuring consumer confidence within the life sciences. So we track sentiment, we track funding, we track barriers and opportunities, as well as purchase intentions. And we do it every six months for the coming six months of the year."   "So here you have to take into consideration that we talk to scientists globally in this survey, and we talk to them from a variety of different settings and environments. So while about half of our respondents are from academic institutions around the world, the other half are in a variety of industries, mostly biopharma. And we see here that there's a shift, there's a difference in sentiment and in optimism, in outlook, in interest in science, in the applicability of science, and how these different groups are managing it. As you can imagine, the academics are feeling a lot more pressure."   "The consumer sentiment is lower, and there's definitely more fear in that cohort of scientists. Biopharma is actually surprisingly more resilient, more forward-looking. So on the biopharma side, what we're seeing is that there's actually surprising resilience and there's forward-looking intentions. And we see that scientists are actually looking forward to applying new techniques and new technologies that are coming online, and they have more confidence in their ability to make progress for the second half of 2025."   #LINUSGroup #Lifesciences #Healthcare #AIHealthcare #Stategy #Scientists #AI #MedAI thelinusgroup.com Download the transcript here

Dr. Kamal Golla, Vice President of Clinical Technologies and Performance at Evolent, highlights the complexities of cancer care and the need for care navigation to address medical, emotional, financial, and logistical challenges. This comprehensive approach leads to improved treatment adherence and patient satisfaction while reducing emergency room visits and hospitalization. The care team serves as an extension of the medical decision-makers, helping to manage care across multiple specialists, advising on overcoming side effects, and reducing logistical hurdles to ease the burden on physicians and caregivers, ultimately improving patient outcomes. Kamal explains, "Cancer care navigation is really about creating a roadmap for patients. It's making sure they're not left alone to piece together appointments, interpret side effects, or figure out how to pay for medications. The role of a navigator here is really to guide them through the whole journey. That includes the medical components that many folks are familiar with, but also the emotional, financial, and logistical components that come with a cancer diagnosis. The evidence is really clear, given that more than half of emergency department visits and nearly a quarter of hospitalizations related to cancer care are actually avoidable, that responding rapidly to these situations is key." "In our navigation program, we are rooted in patient-centric navigation, meaning we ask them what the transportation difficulties are that they might face. Who is your caregiver and their support? What do you do for work? What are your cultural and religious beliefs? All of those play a big part in dealing with the new diagnosis of cancer. We want all of that information to be able to provide a very personalized journey."  #Evolent #Oncology #CancerCare #CareNavigation #HealthcareInnovation #DigitalHealth #PersonalizedCare #PatientCenteredCare #Evolent #Careology Evolent.com Download the transcript here

Bill Snyder, CEO and Founder of Cylinder, is addressing the high prevalence of digestive health issues using a virtual care model to provide access to a coordinated care team, including dieticians and health coaches, to offer personalized care plans. GI conditions are complex and involve a combination of genetic predisposition, environmental factors, and dietary influences. There are strong correlations between the gut and brain, as well as digestive health and various physical and mental conditions. Cylinder fills a gap in traditional GI care, where physicians often lack extensive nutritional training. Bill explains, "First and foremost, we think about the patients that we serve, and the patients that we serve come to us from across the country. We serve patients in every state across the US, and they suffer from a variety of GI-related conditions. That's things like ulcerative colitis, Crohn's disease, irritable bowel syndrome, and GERD. It's also a large population who don't have a formal diagnosis, but are symptomatic of GI conditions. So they may have chronic bloating, chronic constipation, and chronic heartburn, and they may not know what the underlying cause is. And then we also reach those members through our clients, which are large self-funded organizations and health plans. People traditionally gain access to Cylinder as part of their employee benefits package." "But there's also a lot that we continue to understand in terms of our overall digestive health system connection. The gut-brain axis, which serves as a bilateral feedback loop between the gut and the brain, is where we found that your digestive health often correlates with your mental health, and vice versa. So we know that some of the reasons for the onset of these conditions can be genetic, but to your point, we're also seeing a lot of impact from our environment and certainly from the foods we eat. And so as you think about the American diet, and as you think about how that's changed over the past several decades, we're seeing an increase in the incidence of these conditions and an increase in people who are presenting with these symptoms and not really sure where to go or what to do." #CylinderHealth #GIhealth #digestivehealth #cylinderhealth #GIcare #virtualhealth #employeebenefits  cylinderhealth.com Download the transcript here

Pat Michael, Director of Patient Contact Services at Nebraska Medicine, highlights the challenges of high-volume patient contact centers and how agentic AI can improve operational efficiency, enhance patient access, and allow human agents to focus on more complex and critical calls.  The AI agent offers patients self-service options for scheduling, cancellations, and medication refills, resulting in a 40% reduction in call volume to human operators. Integrating AI into the contact center also enables the prioritization of time-sensitive calls, such as those related to organ transplant coordination. Pat explains, "I'm the Patient Contact Services Director for Nebraska Medicine, which means I oversee our three main contact centers. They're our ambulatory contact center, which takes and schedules all the calls for our ambulatory clinic, and our radiology contact center, which schedules all of our outpatient radiology services. And then our medical communication center, which is our 24-hour-a-day, seven-day-a-week operation with our hospital operators and a group of triage nurses."   "So, some of the challenges that we had are that one of the big things is that we deal with the sheer volume of calls coming into the contact center. And so through the three contact centers, we have about 2.5 million calls that come in, but they're not evenly distributed. They come in when they come in. And so the key to success is managing all these complex calls while ensuring accuracy in the call handling. And what does that mean in the simplest terms? You have to have time to handle the calls accurately. Are we actually staying ahead of the volume, or are we just trying to catch up?"  #NebraskaMedicine #ActiumHealth #AIAgents #PatientEngagement #healthtech #AgenticAI #automation Nebraskamed.com Download the transcript here

Dr. Peter Altman, President and CEO of BioCardia, is focused on treating ischemic heart failure and chronic myocardial ischemia using autologous cells from the patient's bone marrow.  The company has developed a cost-effective model that utilizes a pre-procedure diagnostic to select the optimal patients for this point-of-care system, which processes their cells in a single procedure. A key technology is the Helix catheter system, which enables minimally invasive delivery of cells into the heart, aided by the Heart3D Fusion imaging platform that provides a 3D map for precise cell delivery. Peter explains, "BioCardia's focus is on ischemic etiology of heart disease. This is heart disease that results from poor perfusion, typically following, for example, a heart attack, which is an ischemic disease. And the two diseases we're working on are ischemic heart failure, which is often characterized by a large dilated heart. And in the second is chronic myocardial ischemia, which is characterized by what's called refractory angina or chest pain that actually can be incredibly severe. And so are our focus areas. And we're advancing cell therapies that have been shown to inherently improve the cells we're looking at, which are cells from the bone marrow space, the mononuclear cells that contain the CD34 and CD133 cell populations. They're actually involved in forming new microvasculature and supply." "What we've done is come at it from a different perspective. Instead of selecting the cells and then manufacturing in a remote facility, we have a pre-procedure diagnostic that enables us to select the patients who have appropriate cells and then process them with a point-of-care cell processing platform, which involves just a simple disposable cartridge. And then we can treat these patients in a standard interventional cardiology setting at relatively low cost compared to all cell therapies."      #BioCardia #HeartDisease #AutologousCellTherapy #CellTherapy #3DImaging #Heart3DFusion #CardiAMP biocardia.com Download the transcript here